Needham Reiterates Buy Rating on Harmony Biosciences, Keeps $50 Target
Needham reiterated its Buy rating and $50 price target. The target implies 31.8% upside from the Oct. 16 close of $37.95.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.